Literature DB >> 7710947

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.

K Pryor1, J Goddard, D Goldstein, P Stricker, P Russell, D Golovsky, R Penny.   

Abstract

A cytotoxicity assay was used to study the action of bacillus Calmette-Guerin (BCG) and cytokines on four human bladder cancer cell lines. Monocytes and lymphocytes from peripheral blood were incubated with or without BCG or cytokines for 24 h, after which [3H]thymidine-labelled target cells were added and the 72 h percentage specific release determined. BCG had a direct cytotoxic effect against tumour cells and significantly enhanced monocyte/macrophage and enhanced lymphocyte cytotoxicity against one cell line (UCRU-BL-17). Supernatants (SNs) from BCG-activated monocytes/macrophages and lymphocytes increased the percentage specific release of [3H]thymidine from UCRU-BL-17 cells. Interferon alpha (IFN-alpha) and interleukin 2 (IL-2) were cytotoxic towards UCRU-BL-17. No synergy occurred between BCG and cytokines at the concentrations tested. The results suggest that BCG is superior to IFN-alpha, interferon gamma (IFN-gamma) and IL-2 in enhancing cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710947      PMCID: PMC2033737          DOI: 10.1038/bjc.1995.155

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.

Authors:  M Peuchmaur; G Benoit; A Vieillefond; A Chevalier; G Lemaigre; E D Martin; A Jardin
Journal:  Urol Res       Date:  1989

2.  Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation.

Authors:  P J Russell; M Jelbart; E Wills; S Singh; J Wass; J Wotherspoon; D Raghavan
Journal:  Int J Cancer       Date:  1988-01-15       Impact factor: 7.396

3.  Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

Authors:  D Goldstein; S M Bushmeyer; P L Witt; V C Jordan; E C Borden
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

4.  Immunohistochemical identification of lymphocyte subsets and macrophages in normal human urothelium using monoclonal antibodies.

Authors:  M I el-Demiry; T B Hargreave; A Busuttil; K James; G D Chisholm
Journal:  Br J Urol       Date:  1986-08

5.  Cytotoxicity by macrophages and monocytes.

Authors:  R A De Weger; B A Runhaar; W Den Otter
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

6.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

7.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Authors:  A Thanhäuser; A Böhle; H D Flad; M Ernst; T Mattern; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.

Authors:  F M Torti; L D Shortliffe; R D Williams; W C Pitts; R L Kempson; J C Ross; J Palmer; F Meyers; M Ferrari; J Hannigan
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

9.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity.

Authors:  T L Ratliff; D Gillen; W J Catalona
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

Review 10.  Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.

Authors:  F M Torti; B L Lum
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

View more
  18 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

3.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 4.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

5.  A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

Authors:  Y Luo; A Szilvasi; X Chen; W C DeWolf; M A O'Donnell
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

Review 6.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

Review 7.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

8.  Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro.

Authors:  K Pryor; P Stricker; P Russell; D Golovsky; R Penny
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

9.  Prospective study of immunomodulation in osteoarticular tuberculosis non responsive to anti tubercular therapy.

Authors:  B P Sharma; Amit Kumar; Saubhik Das; Shambhu Prasad
Journal:  J Clin Orthop Trauma       Date:  2017-07-03

Review 10.  Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Authors:  Yi Luo; Jonathan Henning; Michael A O'Donnell
Journal:  Clin Dev Immunol       Date:  2011-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.